Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2010 Nov;88(5):610-9.
doi: 10.1038/clpt.2010.178. Epub 2010 Sep 29.

Update on new antivirals under development for the treatment of double-stranded DNA virus infections

L K Dropulic  1 , J I Cohen
Affiliations
Review

Update on new antivirals under development for the treatment of double-stranded DNA virus infections

L K Dropulic et al. Clin Pharmacol Ther. 2010 Nov.

Abstract

All the currently available antiviral agents used in the treatment of double-stranded (ds) DNA viruses, with the exception of interferon-α, inhibit the same target, the viral DNA polymerase. With increasing reports of the development of resistance of herpes simplex virus (HSV), cytomegalovirus (CMV), and hepatitis B virus (HBV) to some of these drugs, new antiviral agents are needed to treat these infections. Additionally, no drugs have been approved to treat several DNA virus infections, including those caused by adenovirus, smallpox, molluscum contagiosum, and BK virus. We report the status of 10 new antiviral drugs for the treatment of dsDNA viruses. CMX-001 has broad activity against dsDNA viruses; 3 helicase-primase inhibitors, maribavir, and FV-100 have activity against certain herpesviruses; ST-246 inhibits poxviruses; GS-9191 inhibits papillomaviruses; and clevudine and emtricitabine are active against HBV. Most of these drugs have completed at least phase I trials in humans, and many are in additional clinical trials.

PubMed Disclaimer

Conflict of interest statement

CONFLICTS OF INTEREST

J.I.C. has a collaborative research agreement with Chimerix which provides CMX001 for in vitro testing.

Figures

Figure 1
Figure 1
Structures of CMX-001 (A), BAY 57-1293 (B), BILS 179 BS (C), ASP2151 (D), FV-100 (E), Maribivar (F), ST-246 (G), GS-9191 (H), Clevudine (I), Emtricitabine (J).
See this image and copyright information in PMC

References

    1. Beadle JR, et al. Alkoxyalkyl esters of cidofovir and cyclic cidofovir exhibit multiple log enhancement of antiviral activity against cytomegalovirus and herpes virus replication in vitro. Antimicrob Agents Chemother. 2002;46:2381–2386. - PMC - PubMed
    1. Huggins JW, Baker RO, Beadle JR, Hostetler KY. Orally active ether lipid prodrugs of cidofovir for the treatment of smallpox. Antiviral Res. 2002;53 (A66):104.
    1. Kern ER, et al. Enhanced inhibition of orthopoxvirus replication in vitro by alkoxyalkyl esters of cidofovir and cyclic cidofovir. Antimicrob Agents Chemother. 2002;46:991–995. - PMC - PubMed
    1. Williams-Aziz SL, et al. Comparative activities of lipid esters of cidofovir anc cyclic cidofovir against replication of herpesviruses in vitro. Antimicrob Agents Chemother. 2005;49:3724–3733. - PMC - PubMed
    1. Randhawa P, Farasati NA, Shapiro R, Hostetler KY. Ether lipid ester derivatives of cidofovir inhibit polyomavirus BK replication in vitro. Antimicrob Agents Chem. 2006;50:1564–1566. - PMC - PubMed